{"denoms":[{"counts":[{"groupId":"BG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"Patients received 100mg desipramine hydrochloride PO daily from Day -3 to Day +4 (8 days total) and filgrastim PO BID from Day +1 to Day +4. Complete blood count (CBC) and peripheral blood CD34+ counts were determined on Day +4 and Day +5. Leukapheresis was started when peripheral blood CD34+ count exceeded 10/uL. If CD34+ counts were \\<10/uL on Day +5, plerixafor was added as a salvage therapy. Daily leukapheresis was performed with four times the estimated blood volume during each collection until a target cell dose of at least 5x10\\^6 cells/kg was reached. If the collected CD34+ cell dose was \\<0.5x10\\^6 on two consecutive days, aperheris was stopped and the patient was taken off study.\n\nDespiramine hydrochloride: PO Filgrastim: PO","id":"BG000","title":"Treatment (Desipramine, Filgrastim)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"58","upperLimit":"70","value":"59.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Age range of the 6 patients who completed the study.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Gender of the 6 patients who completed the study.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"United States"}],"paramType":"NUMBER","populationDescription":"Region of enrollment of the 6 patients who completed the study.","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"No"}]}],"description":"Number of patients who had received Lenalidomide prior to the trial.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of patients who had received Lenalidomide prior to the trial who completed the study.","title":"Prior Lenalidomide therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"One prior chemotherapy treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":">1 prior chemotherapy treatment"}],"description":"Number of prior chemotherapy treatments.","paramType":"NUMBER","populationDescription":"Number of prior chemotherapy treatments for the study participants who completed the trial.","title":"Prior chemotherapies","unitOfMeasure":"participants"}],"populationDescription":"The respective baseline measures were provided for the 6 participants who completed the protocol."}